MY PICK IS ELN

[kingofthehill]

rumor has it the trials are being restarted, thats why the volume has been huge for the past week or so, place your bets call options could return 200-300% on ELN in a short time,

Fidelity and Etrade show no ELN shares to short,

short position on Elan is 39 million shares!...enjoy covering if you short on the wrong day ...lol

[New-born baby]

Sister Stock

rumor has it the trials are being restarted, thats why the volume has been huge for the past week or so, place your bets call options could return 200-300% on ELN in a short time,

Fidelity and Etrade show no ELN shares to short,

short position on Elan is 39 million shares!...enjoy covering if you short on the wrong day ...lol

King,

Here's a sister stock you might look into: BBW. 39% of all the float is shorted!

If ELN could pull a short squeeze off (and with this wild stock, I almost guarantee it), it is really going to bounce.

[Websman]

King,

Here's a sister stock you might look into: BBW. 39% of all the float is shorted!

If ELN could pull a short squeeze off (and with this wild stock, I almost guarantee it), it is really going to bounce.

I hope ELN pulls off a big short squeeze...especially since I just bought it.

[Websman]

I hope ELN pulls off a big short squeeze...especially since I just bought it.

So far so good. Now all we need is a little good news.

[noshadyldy]

spike

Thanks, you great guy you!

Just made some mo money thanks to you!

BTW - may 26 tomorrow - big annual presentation at ELN
could be interesting.

[spikefader]

Thanks, you great guy you!

Just made some mo money thanks to you!

BTW - may 26 tomorrow - big annual presentation at ELN
could be interesting.

Great! You're welcome. May this puppy rumble north and the cash roll in for us Lookin' at the chart, I think Elvis has left the building!

[Websman]

News looks good for ELN. Maybe we'll see some gains today.



"Elan still making suspended drug

May 26, 2005 11:02
The chief executive of pharmaceutical company Elan has said he is very confident that its suspended multiple sclerosis drug Tysabri will find a pathway back to the market.

He has also revealed that the company is continuing to manufacture the drug, as the take-up had been 'extraordinary' when it had been on the market, and Elan did not want the drug to be unavailable at any stage.

Multiple sclerosis drug Tysabri was withdrawn from the market in February, wiping 70% off the value of the company, after it was discovered two patients treated with the drug developed PML, a brain disease. One of the patients died. "

[Websman]

King, it looks like I've joined you just in time. It looks like ELN will open with a gap up.

[kingofthehill]

news looks great 39 million shares short, Biogen who owns the license for TYSABRI in the USA talks next week, any formal announcement would be thiers to make next week.

[kingofthehill]

Dow Jones Real-Time News for InvestorsSM
08:43 a.m. 05/26/2005

Martin reiterated that Tysabri stops the progression of MS, while other MS drugs only slow its progression; this is a "critical" piece of information Elan will raise when it formally meets with the FDA, he added.

He said Biogen and Elan "may never have a pure scientific argument" as to what caused the PML based only on three cases. "That isn't our goal and the FDA knows that," he said. "It's a question of risk assessment."

Martin also said Biogen is continuing to manufacture Tysabri, partly due to its "extraordinary" take-up when it was on the market, and so the companies are braced for its return to market.

The three PML Tysabri patients all had conditions that suppressed their immune systems, Martin added, but said that none of the three were HIV patients; he declined to reveal how many of the 3,000 trial patients are immuno-suppressed.

Elan, which faces more than $1.1 billion in debt repayments in 2008, would suffer a major blow if Tysabri was withdrawn permanently, as it has relied on the drug for most of its future revenue growth.

But Martin said there are "no concerns whatsoever about our 2008 debt obligation...We have the financial wherewithal to grow other parts of the business."

Elan also said that Phase II data from its Alzheimer's drug AAB-001 is due to be completed by the end of 2006 "We have a good understanding of what the drug does to cognitive memory and (patients') quality of life," Martin said.

At 1345 Thursday, Elan was up 3.2%, or 18 cents, at EUR5.75 on the Irish Stock Exchange after plummeting from EUR20.30 after Tysabri's suspension in February.

"As time has gone on and there have been no other reported cases of PML, there's more chance that Tysabri is going to come back to market," Goodbody's Hunter added.

Company Web site: hxxp://www.elan.com

-By Quentin Fottrell, Dow Jones Newswires; +353 1 676 2189; [email protected]

[New-born baby]

Good work, Spock

King, it looks like I've joined you just in time. It looks like ELN will open with a gap up.

Very nice timing, Spock! Must be that Vulcan 6th sense of yours.

[Websman]

Very nice timing, Spock! Must be that Vulcan 6th sense of yours.

Just the night before last, I had a dream that I bought ELN and it shot up immediately afterwards.

Pure coincidence....but strange.

[kingofthehill]

ok its early ...but like i said OPTIONS ARE UP 300% TODAY !!!!!


JAN 06 STRIKE 22.50 UP 300%


JAN 06 STRIKE 17.50 UP 75 %

[Websman]

I'm trying not to get too excited...but I think I just pissed my pants. It's going higher.

[noshadyldy]

I'm trying not to get too excited...but I think I just pissed my pants. It's going higher.

LOLOLOLOLOL!!!